COSA 2015* , ,
Presentations this author is a contributor to:
Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC) (#212)
3:00 PM
Elizabeth R Plimack
Posters1